Bill would broaden evidence considered for rare and life‑threatening conditions in state health‑tech reviews
Get AI-powered insights, summaries, and transcripts
Subscribe
Summary
SB 59 15 would direct the Health Technology Assessment Program to prioritize technologies recommended in Medicare or national guidelines and require broader evidence review (including non‑randomized trials) for life‑threatening or rare conditions so some treatments are not excluded from coverage.
Committee staff opened Feb. 18 with a briefing on Senate Bill 59 15, which revises the Health Technology Assessment Program to add a prioritization category for technologies recommended for Medicare populations or in national treatment guidelines and to require the clinical committee to consider all clinical trials and peer‑reviewed literature for life‑threatening or rare diseases. Staff said the program must post requests for assessments online within 30 days and that clinical reviews must be completed within 180 days.
Rare‑disease parents and clinicians urged the change, arguing that traditional randomized controlled trials are often infeasible or unethical for rare conditions. Carolina Sommer, a rare disease parent, said the bill “does not lower the bar for safety,” but asks assessors to consider all valid evidence so treatments for rare conditions are not automatically excluded. Testimony included clinicians and patient advocates who said current review processes are rigid and can deny access to recommended therapies and devices for public program enrollees.
The committee did not vote at the hearing. Sponsors and proponents emphasized the bill’s intent to inject flexibility and clinical judgment into assessment decisions for small patient populations.